Atlas Trials

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Clinical trial NCT03674567 · COMPLETED

Trial details

NCT number
NCT03674567
Sponsor
RAPT Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Cancer
Start date
2018-09-25
Primary completion
2024-12-31
Enrollment
323

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.